WHO Pesticide Evaluation Scheme (WHOPES)

WHOPES recommendations and reports of WHOPES Working Group meetings

WHOPES Working Group meetings



Report of the 15th whopes working group meeting – Review of Olyset® Plus, Interceptor® LN, Malathion 440 EW, Vectobac® GR, 18—22 June 2012, Geneva, World Health Organization
Ref: ISBN 978 92 4 150408 9 and WHO/HTM/NTD/WHOPES/2012.5 (web only





Report of the 14th WHOPES Working Group meeting – Review of Spinosad® EC, Lifenet® LN, MagnetTM LN, Royal Sentry® LN, Yahe® LN, 11—15 April 2011, Geneva, World Health Organization
Ref: WHO/HTM/NTD/WHOPES/2011.7 (web only)







Report of the 13th WHOPES Working Group meeting – Review of Olyset® LN, Dawaplus® 2.0 LN, Tianjin Yorkool® LN, 28—30 July 2009, Geneva, World Health Organization, 2009
Ref: WHO/HTM/NTD/WHOPES/2009.5







Report of the 12th WHOPES Working Group meeting – Review of Bioflash® GR, Permanet® 2.0, Permanet® 3.0, Permanet® 2.5, Lambda-cyhalothrin LN.
8—11 December 2008, Geneva, World Health Organization, 2008
Ref: WHO/HTM/NTD/WHOPES/2009.1








Report of the 11th WHOPES Working Group meeting – Review of Spinosad 7.48% DT, Netprotect®, Duranet®, Dawaplus®, Icon® maxx.
10—13 December 2007, Geneva, World Health Organization, 2007
Ref: WHO/HTM/NTD/WHOPES/2008.1








Report of the 10th WHOPES Working Group meeting – Review of Spinosad 0.5% GR and 12% SC, Lambda-Cyhalothrin 10% CS, K-O TAB 1-2-3® Interceptor®.
11—14 December 2006, Geneva, World Health Organization, 2006
Ref: WHO/CDS/NTD/WHOPES/2007.1









Report of the 9th WHOPES Working Group meeting – Review of Dimilin® GR and DT, Vectobac® DT, Aqua K-othrine® and Aqua Reslin Super®.
5—9 December 2005, Geneva, World Health Organization, 2005
Ref: WHO/CDS/NTD/WHOPES/2006.2









Report of the 8th WHOPES Working Group meeting – Review of Novaluron 10% EC. 1—3 December 2004, Geneva, World Health Organization, 2005
Ref:WHO/CDS/WHOPES/2005.10










Report of the 7th WHOPES Working Group meeting – Review of VectoBac WG, PermaNet and Gokilaht 5EC. 2—4 December 2003, Geneva, World Health Organization, 2004
Ref:WHO/CDS/WHOPES/2004.8









Report of the 6th WHOPES Working Group meeting – Review of deltamethrin 25% WG & WP and Agnique MMF. 6—7 November 2002, Geneva, World Health Organization, 2002
Ref:WHO/CDS/WHOPES/2002.6









Report of the 5th WHOPES Working Group meeting – Review of Olyset Nets and bifenthrin 10%WP, 30—31 October 2001, Geneva, World Health Organization, 2001
Ref:WHO/CDS/WHOPES/2001.4










Report of the 4th WHOPES Working Group meeting – IR3535, KBR3023, (RS)-methoprene 20%EC, pyriproxyfen 0.5%GR and lambda-cyhalothrin 2.5%CS. 4—5 December 2000, Geneva, World Health Organization, 2001
Ref:WHO/CDS/WHOPES/2001.2









Report of the 3rd WHOPES Working Group meeting – deltamethrin 1%SC and
25%WT and etofenprox 10%EC and 10%EW. 23—24 September 1999, Geneva, World Health Organization, 1999
Ref:CDS/CPE/WHOPES/99.4









Report of the 2nd WHOPES Working Group meeting – Review of alpha-cypermethrin 10%SC and 5%WP and cyfluthrin 5%EW and 10%WP. 22—23 June 1998, Geneva, World Health Organization, 1998
Ref:WHO/CTD/WHOPES/98.10









Report of the first WHOPES Working Group meeting – 26—27 June 1997. Geneva, World Health Organization, 1997
Ref:CTD/WHOPES/97.5






Share